Board meeting on Nov 3 to approve Q2 FY26 results

Results View source PDF Explain this filing

GLAXO · price

Loading chart…

▲ positive · ▼ negative · ● neutral filings · teal = economic event · numbered = multiple that day (click to pick). Times IST.

Price reactionminutes from the announcement price · days from the prior close

+0.0%Reaction day

₹2537.20

prior close

₹2536.30

announcement price

After-mkt

timing

Nifty Midcap 150market-0.0%+0.1% vs market

Pharmaceuticals peers, median of 172sector-0.0%+0.1% vs sector

On the reaction day the stock moved 0.1 pts more than Nifty Midcap 150 and 0.1 pts more than its Pharmaceuticals peers, over the same two closes: a difference in percentage points, not a measure of what the filing did.

Minutes after the announcementfrom the announcement price · no benchmark

Stock

-0.5

10m

-0.6

15m

-0.6

30m

-0.4

Sessions after the filingfrom the prior close

StockMarketvs marketSectorvs sector

Reaction day

+0.0-0.0+0.1-0.0+0.1

Next day

-0.3-0.3+0.1-0.8+0.5

+1.2-0.4+1.6-0.6+1.8

-1.4-1.5+0.1-1.9+0.5

-3.4-2.9-0.5-3.5+0.2

-3.9-3.7-0.3-4.4+0.5

-3.5-4.7+1.1-4.4+0.9

15d

—————

UpDownMarket · Nifty Midcap 150Sector · Pharmaceuticals peers, median of 172Pending

Minute windows have no benchmark: there is no intraday index history to compare against.

AI summary

GlaxoSmithKline Pharmaceuticals has informed BSE that its Board of Directors will meet on Tuesday, 3 November 2026 to consider, approve and take on record the unaudited financial results for the second quarter and half year ended 30 September 2026. This is a routine pre-results intimation under SEBI LODR regulations.

Likely market impact

Investors should watch for the Q2 FY26 results on or after 3 Nov 2026. No price-moving information is disclosed in this notice.